SABCS: Positive Outcomes Seen When Pausing Endocrine Therapy to Become Pregnant

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 7, 2023.

By Elana Gotkine HealthDay Reporter

THURSDAY, Dec. 7, 2023 -- Among patients with hormone receptor-positive breast cancer who paused endocrine therapy (ET) to become pregnant, fertility preservation and/or assisted reproductive technologies (ART) do not adversely affect three-year cancer recurrence rates, according to a study presented at the annual San Antonio Breast Cancer Symposium, held from Dec. 5 to 9 in San Antonio.

Hatem A. Azim Jr., M.D., Ph.D., from the School of Medicine and Breast Cancer Center at the Tecnológico de Monterrey in Cordoba, Mexico, and colleagues conducted a secondary analysis of an international, single-arm, prospective trial that enrolled patients aged 42 years and younger with stage 2 to 3 hormone receptor-positive breast cancer who had received 18 to 30 months of ET and paused ET to become pregnant.

The researchers found that 74 percent of the 497 patients reported at least one pregnancy. Young age was the only factor associated with shorter time to pregnancy in a multivariable model. At diagnosis and prior to enrollment, 36.0 percent of the patients had undergone ovarian stimulation for embryo/oocyte cryopreservation, of whom 37.9 percent reported cryopreserved embryo transfer after enrollment. Overall, 43.3 percent of the patients reported using ART after enrollment, including ovarian stimulation for in vitro fertilization or intracytoplasmic sperm injection (37.2 percent). The only ART independently associated with a higher chance of pregnancy was cryopreserved embryo transfer (odds ratio, 2.41) in a multivariable model. At three years, the cumulative incidence of breast cancer-free interval events was similar for those who underwent ovarian stimulation for cryopreservation at diagnosis and before enrollment and for those who did not (9.7 versus 8.7 percent).

"Participants who underwent cryopreserved embryo transfer during the study had higher pregnancy rates with no apparent short-term detrimental impact on breast cancer outcome," Azim said in a statement.

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2023-12-08 02:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords